Drug
Dupilumab clinical trials
Also written Dupixent, REGN668 and SAR231893.
Keep track of what changes. Save the dupilumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
174 studies that test it; most in 2020 (23)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 16 |
| 2019 | 10 |
| 2020 | 23 |
| 2021 | 19 |
| 2022 | 15 |
| 2023 | 20 |
| 2024 | 22 |
| 2025 | 8 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 24
Who runs them
Industry 95 · Other 79
Sanofi (49) · Regeneron Pharmaceuticals (40) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · AbbVie (4) · University of California, San Francisco (4) · Icahn School of Medicine at Mount Sinai (4) · Brigham and Women's Hospital (3) · University of Michigan (3)
Often tested with
Tested in the same studies.
Upadacitinib (4) · Ustekinumab (3) · Itepekimab (3) · Cemiplimab (3) · Adalimumab (2) · Guselkumab (2) · Triamcinolone Acetonide (2) · Fluticasone (2)
Studies
Open first, then newest update. How each study uses dupilumab is read from its arms, and is right about nine times in ten.
Testing it · 174
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.RecruitingPhase 4SanofiNCT07053423Written as Dupilumab
- This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationRecruitingPhase 4Regeneron PharmaceuticalsNCT07587658Written as dupilumab
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)RecruitingPhase 3SanofiNCT05263206Written as Dupilumab
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisRecruitingPhase 3SanofiNCT06293053Written as Dupilumab
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06477653Written as dupilumab
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRecruitingPhase 3Regeneron PharmaceuticalsNCT07112378Written as dupilumab
- Dupilumab in the Treatment of Pediatric Alopecia AreataRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT05866562Written as Dupilumab
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung CancerRecruitingNot applicableCentre hospitalier de l'Université de Montréal (CHUM)NCT06743581Written as Dupilumab
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)Enrolling by invitationPhase 3SanofiNCT06191315Written as Dupilumab
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesRecruitingPhase 1/2Dan FengNCT07277322Written as Dupilumab
- Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe AsthmaRecruitingPhase 4Sally E. Wenzel MDNCT04743791Written as Dupilumab
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCRecruitingPhase 1/2Icahn School of Medicine at Mount SinaiNCT06088771Written as Dupilumab
- Regeneron AA Multicenter (Dupilumab)RecruitingPhase 2Emma GuttmanNCT05551793Written as Dupilumab
- Molecular Signatures of Cutaneous Dupilumab ResponseRecruitingPhase 4University of California, San FranciscoNCT05858619Written as Dupilumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Dupilumab
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingEarly Phase 1Rima PatelNCT06637306Written as Dupilumab
- Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.Enrolling by invitationEarly Phase 1Mayo ClinicNCT07358234Written as Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin DisordersRecruitingEarly Phase 1Northwestern UniversityNCT05649098Written as Dupilumab
- Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic DermatitisRecruitingPhase 4Northwestern UniversityNCT05042258Written as Dupilumab
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07330934Written as Dupilumab
See all 174 studies that test dupilumab →
Given in every arm · 5 — dupilumab is usual care beside what is tested
- Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD PatientsNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06465732Written as Dupilumab
- Dupilumab_Metastatic NSCLCActive, not recruitingPhase 1/2Thomas MarronNCT05013450Written as Dupilumab
- Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)CompletedPhase 3SanofiNCT04681729Written as Dupilumab SAR231893
- Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)CompletedPhase 3SanofiNCT04180488Written as Dupilumab SAR231893
- Study of Dupilumab Auto-injector Device When Used by Patients With Atopic DermatitisCompletedPhase 1Regeneron PharmaceuticalsNCT03050151Written as Dupilumab
As the comparator · 17 — what is tested is compared with dupilumab
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingPhase 3PfizerNCT07783425Written as Dupilumab
- A Phase III Study of GS101 Injection to Dupixent®RecruitingPhase 3Jiangsu Genscend Biopharmaceutical Co., LtdNCT07386743Written as DUPIXENT®
- A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07754786Written as Dupilumab Injection
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07399067Written as Dupilumab
- A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male SubjectsNot yet recruitingPhase 1Gan & Lee Pharmaceuticals.NCT07334496Written as Dupilumab Injection
- Complete Remission After Treatment With Biologics for Nasal PolypsRecruitingPhase 4Rigshospitalet, DenmarkNCT07268313Written as DUPIXENT®
- A Phase Ⅲ Comparative Study of QL2108 to Dupixent®Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06884891Written as Dupixent®
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06868212Written as Dupilumab
- An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisActive, not recruitingPhase 1Apogee Therapeutics, Inc.NCT07027527Written as Dupilumab
- A Phase I Study of 9MW4113 Injection Versus Dupixent®Active, not recruitingPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT07791342Written as Dupilumab
- A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)TerminatedPhase 2Janssen Research & Development, LLCNCT06881251Written as Dupilumab
- A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese VolunteersActive, not recruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT07502534Written as DUPIXENT® (dupilumab)
- A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®CompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT06614907Written as Dupixent®
- A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe ADCompletedPhase 2LEO PharmaNCT05470114Written as Dupixent®
- A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic DermatitisTerminatedPhase 2Janssen Research & Development, LLCNCT04791319Written as Dupilumab
- Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedPhase 3PfizerNCT04345367Written as Dupilumab 300 mg
- Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedPhase 3PfizerNCT03720470Written as Dupilumab
Codes
What other systems call dupilumab · ClinicalTrials.gg INT006309
- MeSH (NLM) C582203dupilumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 420K487FSGDUPILUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1876376Confirmed FDA, Wikidata
- Wikidata Q5315925dupilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C162455DupilumabOne source FDA
- DrugBank DB12159One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582203 | dupilumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 420K487FSG | DUPILUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1876376 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5315925 | dupilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C162455 | Dupilumab | One source FDA |
| DrugBank | DB12159 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.